Acne is long-lasting skin inflammation, particularly on delicate skin areas like face, neck, shoulders, upper arms, back, and chest. It is most common in the age group of 11–30 years. The anti-acne treatment is anticipated to observe a considerable development because of the expanding prevalence of acne across the globe. The global acne treatment product pipeline comprises a total of 64 programs at various stages of clinical trials, and 41% of products are in the pre-clinical stage. There are multiple promising molecules in clinical development that may potentially change the acne treatment market in the future.
As per the World Health Organization, acne is the 8th most prevalent disease around the world. It occurs more commonly during adolescence and affects over 95% of young men and almost 85% of young women during this stage. This is further supported by an unhealthy lifestyle and growing air pollution across the globe.
In the last few years, the market has witnessed a significant rise in the number of e-commerce websites selling anti-acne medications. This has also helped the market players in easing the marketing efforts even in the most remote locations. Companies such as Neutrogena, L'Oréal, Johnson & Johnson, Proactiv, and Clinique are constantly trying to expand their market reach through different e-commerce platforms. Many products such as anti-pimple facewash, oil-free acne face wash, anti-acne oil control face wash, anti-acne face packs, and anti-acne creams are currently being sold through online pharmacies. Increasing spending on cosmetic products, expanding social networks, growing consumer interest in new and premium products, and rapid urbanization are leading the market growth further. Online cosmetics and anti-acne product markets have witnessed a 25% growth in the last few years. By distributional channel, the online market is holding around 12.5% share of the anti-acne product market.
Growing awareness regarding acne treatments and rising focus on the quality of life and self-esteem, especially in the adult population, are significantly influencing the emotional and mental association with their physical appearance and treatment choices for acne. Today, consumers are increasingly asking for non-invasive cosmetic treatment. This is further giving impetus to the technological advancements in medical and cosmetic devices. For instance, Alma Lasers Ltd provides effective non-invasive laser treatment for acne vulgaris with zero possibility of pain and reduced probability of hyperpigmentation. A chemical peel, photo rejuvenation, and laser acne scare remover are some of the major forms of new non-invasive therapies available in the market. Rapid urbanization and expanded internet connectivity have improved the consumers’ awareness about product availability for acne treatment. Most of the consumers are aware of available treatment options in the market and their adverse effects, which play a key role in the acceptance of the anti-acne treatments and products.
Retinoid and anti-infection agents are the pillars of the anti-acne treatment. In 2017, retinoid dominated the therapeutic class market by revenue, followed by antibiotic products. It is expected that retinoid would prevail as the market pioneers due to its first-line therapeutic actions and pending approvals for pipeline products. Antibiotics are often used in combination therapy with benzoyl peroxide to avoid antibiotic resistance.
The therapeutic model is likely to shift from monotherapy to combination therapy. Combination therapies are picking up growth because of higher efficacy, improved results, reduced resistance, and convenient usage.
Hormonal therapy is generally used in extreme cases in a combination of benzoyl peroxide, antibiotics, and retinoid. In most of the case, oral contraceptions are used as a part of the therapy. This technique is regularly favored by women having acne.
From the last few decades, the demand for minimally invasive acne treatment therapies has been increasing. Today, a number of dermatologists are commonly preferring topical medications to treat acne, owing to its easy availability and better effectiveness with minimal adverse reactions. Today, a range of topical treatment options are available in the market, such as antibiotic creams and gels, vitamin A analog solutions or lotions, Benzoyl peroxide, and salicylic acid creams, gels, and lotions.
The global topical acne treatment market is expected to attain a value of USD 4 billion by the end of the forecast period, at a CAGR of 4.6%. Several players are highly focusing on producing topical treatment products to meet consumer demand. As per the market analysis, topical therapies are holding more than 60% of the market share than other therapies.
In 2016, Accutane, a topical isotretinoin brand, generated a revenue of more than USD 1 billion. It is considered as one of the top-selling topical products in the acne prescription market. Galderma’s ‘Epiduo gel’ (benzoyl peroxide and adapalene) also reported substantial growth in the same year.
In rare cases, dermatologist prescribes oral medications if the underline cause of acne is hormonal imbalance. Many oral corticosteroid products approved by the U.S. FDA are available in the market such as Ortho Tri-Cyclen, Beyaz, and Yaz pills. Some antibiotics are also prescribed in the oral formulation to patients who do not respond to topical products such as tetracycline—minocycline or doxycycline and macrolide antibiotics. Recently, oral antibiotics have started showing dormancy, owing to the development of antibiotic resistance. Some of the oral retinoids like Isotretinoin were also used in the market. However, on account of reported teratogenicity, these products were withdrawn from the market.
North America’s acne treatment market is valued at USD 3 billion and is expanding at CAGR of 4.%. In the region, the use of anti-acne products is growing at a staggering rate. For instance, around 85% of the U.S. population and more than 80% of the Canadian population in the age group of 10 to 24 experience acne at least once in a year, the American Dermatological Association. In line with this, several major market players are putting more effort into exploring more and effective treatment options to strengthen their market position. Johnson & Johnson, Guthy-Renker, Reckitt Benckiser, Galderma Laboratories, GlaxoSmithKline plc, Amgen Inc., Allergan, and Dermira are some of the key players active in the acne treatment market. Key market players often employ strategies such as advancement in R&D activities, out-licensing for manufacturing and development of medications, merger, and acquisition, and strategic partnerships to improve their market share.
In 2018, consumers spent around USD 1 billion on acne treatment medicines in Europe. The europian acne treatment market reported growing at CAGR 4.4% in the years to come. The region is holding about 20% share of the global anti-acne treatment market. This can be attributed to several resurging economies in this region like the U.K, and Germany, large patient population, and rapidly increasing teenage population. Germany is leading the regional market by holding around 20% market share.
Asia Pacific is the fastest growing acne treatment market and is projected to grow at a CAGR of about 5%. The region is housing several economies like India, China, Singapore, and Japan, among others with robust e-commerce and organized retail markets. It has been found that the top 10 players in the region are holding more than 55% share of the regional anti-acne market and more than 50 pharmaceutical companies are actively marketing their products in the acne treatment.
India anti-acne market grew from USD 48 million in 2012 to USD 135 million in 2018. By the end of 2026, the number of people affected by acne in India is estimated to reach 23 million.
The LAMEA acne treatment market is poised to attain a value of USD 800 million by 2027, at a CAGR of 3.3%. This can be attributed to growing awareness regarding skincare, availability of advanced anti-acne treatments, and rising number of teenagers affected by acne vulgaris. Around 70% of the population in Chile and 40% of the population in Colombia have been affected by acne. However, Brazil is dominating the market and is projected to grow at a CAGR of 3.7% in the years to come.
Middle East and Africa are witnessing sluggish growth on account of poor healthcare infrastructure and low disposable income in African countries and stringent government regulations. In the Middle East, Unani medicine or Islamic medicine is more popular treatment options for acne than others.
Some of the key players in the anti-acne market are Allergan Plc., Nestle S.A. (Galderma S.A.), Johnson & Johnson, Amgen Inc., Allergan, Dermira., Pfizer Inc., GlaxoSmithKline Plc (Stiefel Laboratories, Inc.), , Foamix Pharmaceuticals, Daiichi Sankyo Company, Ltd, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.
In 2017, Valeant dominated the anti-acne market due to its wide product offerings and is projected to holding the leading position in the years to come.
Several leading players are highly focused on maintaining their position in the global acne treatment market and are increasingly investing in R&D activities. Reformulation of the existing products is one of the key strategies these players are opting in order to avoid the risk associated with new product development. On the other hand, few players are focusing on increasing their market share through mergers and acquisitions. For instance, a strategic partnership by GlaxoSmithKline Inc. with Stiefel dermatology to develop various dermatological products has helped the company to improve its revenue by acquiring major market share in Europe.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Type (Inflammatory, Hormonal, Cystic), Therapeutic Class, Route of Administration (Topical, Oral, Injectable)|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Allergan plc. (Ireland), Valeant Pharmaceutical International Inc. (U.S), Johnson & Johnson Private Limited (U.S), Galderma S.A (Switzerland), Stiefel Laboratories, Inc. (U.S), GlaxoSmithKline (UK), Teva Pharmaceutical Industries (Israel), Bayer AG (Germany), and Roche Holding AG (Switzerland).|
|Key Market Opportunities||Increasing Prevalence Of The Healthcare It Industry Enhances The Expansion Of The Anti-Acne Treatment Market Share|